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Abstract
Background—Genetic association studies, including a large meta-analysis, report association of
Regulator of G Protein Signaling 4 (RGS4) with schizophrenia in the context of heterogeneity. The
central role of RGS4 in regulating signaling via Gi/o coupled neurotransmitter receptors led us to
hypothesize that there may be RGS4 genotypes predictive of specific disease phenotypes and
antipsychotic treatment responses.
Methods—Subjects were 678 individuals with schizophrenia who participated in the Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE). Among the 678 subjects, the inferred
ancestries were: 198 (29%) ‘Africa only’, 397 (59%) ‘Europe only’ and 83 (12%) ‘Other’. Eight
single nucleotide polymorphisms (SNPs) spanning RGS4 were genotyped. Multiple linear regression
was used to analyze association of RGS4 markers with Positive and Negative Symptoms Scale
(PANSS) scores at baseline and throughout antipsychotic treatment.
Results—Two consecutive markers within RGS4, rs2661319 and rs2842030, were associated with
more severe baseline PANSS total score. Treatment with perphenazine was more effective than
treatment with quetiapine (P=0.010) or ziprasidone (P=0.002) in individuals of inferred African
ancestry and homozygous for the rs951439 ‘C’ allele.
Conclusions—RGS4 genotypes predicted both the severity of baseline symptoms and relative
responsiveness to antipsychotic treatment. Although these analyses are exploratory and replication
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is required, these data provide support for RGS4 in schizophrenia pathogenesis and suggest a
functional role for RGS4 in differential antipsychotic treatment efficacy of schizophrenia.
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Introduction
Schizophrenia is a neurodevelopmental disorder with a substantial genetic component
contributing to increased risk (1). Independent functional and genetic studies indicate that the
regulator of G-protein signaling 4 (RGS4) gene is among a small group of promising disease
vulnerability genes (2,3).
The spatial expression pattern of RGS4 in the adult brain matches closely the dopaminergic
and muscarinic G-protein coupled receptor subtypes targeted by antipsychotic medications
(4–13), suggesting a potential modulatory role for RGS4. The downstream effects of these
receptors are regulated by the activity of RGS4 (14) and other regulators of G-protein signaling
(RGS) proteins, which modulate G-protein coupled receptor signaling by accelerating the
hydrolysis of GTP to GDP (15). The initial focus on RGS4 came from gene microarray and in
situ hybridization studies showing decreased levels of RGS4 mRNA across cortical regions
(4). Decreased levels of RGS4 protein were demonstrated subsequently in frontal cortex of
patients with schizophrenia (16).
Moreover, the approximate genomic region containing RGS4 was implicated in two linkage
studies (17,18) and ranked 13th in a meta-analysis of schizophrenia genomewide linkage
studies (19). The genetic association between RGS4 and schizophrenia was detected initially
in three different populations by Chowdari et al.(20), and confirmed in five subsequent
replication studies (21–25). However, there have been four reports of failures to replicate an
association of RGS4 and schizophrenia (26–29). Further, while the same single nucleotide
polymorphisms (SNPs) in the 5′ region provide the strongest signal in association studies, the
specific haplotypes have not been consistent across sample populations, which can be a
hallmark of a false positive finding. However, a recent meta-analysis of more than 13,000
samples (30) evidenced additional support for the association of two common RGS4 haplotypes
with schizophrenia in the presence of etiological heterogeneity.
The well-known clinical heterogeneity of individuals with schizophrenia may be one
particularly important source of the diversity of genetic associations for a single gene that is
reported across multiple sample populations. Here, we performed a hypothesis-generating
study to begin to dissect this heterogeneity by determining the association of specific alleles
at the RGS4 locus with clinical traits involved in the diagnosis of schizophrenia using the data
generated by the CATIE trial (31,32). Our analyses show that baseline Positive and Negative
Symptoms Scale (PANSS) scores differed among RGS4 marker genotypes. Further, our results
indicate a significant interaction of RGS4 genotype by treatment response that is specific to
individuals of inferred African ancestry, suggesting a complex genetic influence in which the
activity of RGS4 may predict the effectiveness of different pharmacologic treatments.
Methods and Materials
Subjects
The parent study has been described at length elsewhere (31,32). Briefly, all subjects
participated in CATIE (January 2001 to December 2004), a multi-phase randomized controlled
trial of antipsychotic medications involving 1,460 persons with schizophrenia followed for up
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to 18 months. To maximize representativeness, subjects were ascertained from an array of
clinical settings scattered across the United States. No subject was known to be related to any
other subject. All subjects provided written informed consent (including an additional consent
for genetic studies), and the full study protocol was reviewed by IRBs at the University of
North Carolina and at participating study sites. Establishment of schizophrenia diagnosis,
inclusion criteria and exclusion criteria have been described elsewhere (33).
Phenotypes
Analyses were restricted to the length of time to discontinuation of treatment (32) and three
measures derived from the Positive and Negative Symptoms Scale (PANSS), a broadly
accepted measure for reliably ascertaining severity of schizophrenia symptoms (34). The time
to discontinuation of treatment and change in PANSS score are the accepted endpoints of the
CATIE trial (Lieberman et al 2005), and were selected to give the most accurate and reliable
estimates of antipsychotic treatment response in schizophrenia. The PANSS is a 30-question
evaluation of the core symptomatology of schizophrenia. Each question is scored on a scale of
1–7, with “1” indicating that the phenotype is absent and “7” indicating that the phenotype is
extremely severe. Seven questions in the PANSS probe positive symptoms (e.g., delusions and
hallucinations). The next 7 questions examine negative symptoms (e.g., blunted affect and
emotional withdrawal). The final 16 questions concern general psychopathology (e.g., anxiety
and depression). Responses to each question are categorical, but summations of the total score
as well as the three subscales approach normal distributions. PANSS Total scores range from
30 to 210; scores for the PANSS positive and negative scales each range from 7 to 49.
The CATIE treatment protocol is described elsewhere (31,32). Briefly, patients with
schizophrenia were randomly assigned to one of five antipsychotic treatments in Phase 1. The
five treatments in Phase 1 consisted of a first-generation antipsychotic, perphenazine, and
several second-generation (atypical) antipsychotics, olanzapine, quetiaipine risperidone and
ziprasidone. Randomization effectively matched age, sex, education, and baseline PANSS
scores across the five antipsychotic treatment groups in Phase 1 (32). The analyses reported
here are based on the 678 DNA samples available six months before the close of the CATIE
trial.
The primary goal of the CATIE study was to compare the clinical effectiveness of a first-
generation antipsychotic, perphenazine, to four newer antipsychotics (32). Therefore, our
analyses focused on comparing the response to perphenazine versus each of the second-
generation antipsychotics in phase 1 of CATIE. Thus all statistical comparisons are same-
genotype perphenazine versus each of the second-generation antipsychotics. Two major
measures were utilized to infer treatment response: time to discontinuation in Phase I and
change in PANSS score from baseline as measured during Phase I. We recognize, however,
that other variables of the study, such as a patient’s request to switch drug groups by
discontinuing Phase I, may influence these domains in addition to response to the specific drug
treatment.
High molecular weight DNA samples were obtained from all consenting subjects from cell
lines established via EBV transformation at the Rutgers University Cell and DNA Repository
(http://www.rucdr.org/quality_control.html). Sample DNA concentrations were quantified
and normalized via the use of Picogreen dsDNA Quantitation Kits (Molecular Probes, Eugene,
OR) (33).
SNP Selection
SNP selection was based on (20) and the HapMap “CEU” Caucasian panel available in
mid-2003 (35). Based on these data, we chose to genotype RGS4 SNPs SNP4, SNP7 and SNP18
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(20) (rs951436, rs951439, and rs2661319, respectively) plus an additional SNP in the same
LD block (rs2842030). These four SNPs define a LD block including the putative RGS4
promoter through intron 1, but do not cover the RGS4 gene completely. To provide better
coverage of the gene, we genotyped four additional SNPs (rs10759, rs2063142, rs2841959 and
rs2841977).
Comparison to previous reports of RGS4 association
We used the SNP genotype designations of the recent NCBI Genome Build 36.1 (http://
www.ncbi.nlm.nih.gov/SNP); all alleles are indicated in the (+) orientation of chromosome 1.
Previous reports on RGS4 association used the (−) orientation of chromosome 1, and thus
identical alleles and haplotypes are referred to in the reverse complement. For example, we
designate alleles at the rs951436 locus as A/C while Chowdari et al. (20) referred to the identical
SNP (SNP4) as G/T. Thus, rs951436 AA = SNP4 GG, rs951436 CC = SNP4 TT, etc.
Genotyping
Genotyping was performed with TaqMan 5′ exonuclease assays (36) as previously described
(33). The overall no-call rate was 1.4%. Genotyping was conducted blind to all clinical data.
Automated allele calls were made with SDS Data Collection software with all allele calls
reviewed by an experienced operator according to protocol. In order for a SNP to be released
for analysis, we required that: (a) 46 duplicated samples per SNP were in agreement, (b) call
rates exceeded 95%, and (c) the clustering patterns were robust per review by an experienced
technician.
Population stratification is a potential limitation of association studies (37) and is of particular
concern in CATIE, given its explicit intent to ascertain a diverse, clinically representative
sample (31,32). There are two preconditions for population stratification to yield false positive
results (38,39). Because population stratification as a confounder exists only if the phenotypic
distribution and the marker allele frequency differ across ancestral strata, we can determine
the impact of stratification by measuring the marker and disease frequency and predict the
extent of stratification. If there is substantial evidence that population substructure exists in the
overall CATIE sample for the markers studied here, we default to stratified analysis. CATIE
subjects were allowed to select multiple racial categories (White, Black/African-American,
American Indian or Alaska native, Asian, Native Hawaiian or Pacific Islander, or Other) and
were also asked if they were Hispanic or Latino. Inferred ancestry was defined as “Africa only”
if a subject endorsed Black/African-American only, ”Europe only” if a subject endorsed White
only, and “Other” if any other racial category was endorsed.
Statistical Analysis
Data management and statistical analyses were performed with SAS version 9.1.3 (SAS
Institute Inc). For baseline PANSS score analyses, multiple linear regressions were used to
determine genotypic effect while controlling for ancestry, sex, and age. Analyses of time to
discontinuation of treatment were performed using analysis of variance (ANOVA) followed
by Bonferroni multiple comparisons test. Analyses of genotype X treatment interactions were
performed across phase 1 using multiple linear regression with generalized estimating
equations (40) to account for the dependence of measures on the same subject over time. The
model included the covariates of baseline PANSS score, treatment, sex, and age. Haplotype
associations were analyzed with haplo.score (41). HaploView (version 3.2) (42) was used to
calculate Hardy-Weinberg Equilibrium (HWE) and |D′| and r2 linkage disequilibrium
estimates. LD blocks were defined by the Gabriel method (43) in HaploView.
In CATIE, the PANSS was administered at baseline and at multiple time points during
antipsychotic treatment. All statistical analyses used multiple linear regression with GEE
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adjustment for non-independence of PANSS scores in the same individual over time to compare
perphenazine with the second-generation antipsychotics. Significant differences represent
altered PANSS score throughout the treatment period when comparing perphenazine response
to olanzapine, quetiapine, risperidone and ziprasidone responses.
Because this is a hypothesis-generating study, we report uncorrected P values of global and
post hoc multiple comparisons within each set of analyses. After all the hypothesis-generating
analyses were complete, we performed exploratory corrections for multiple comparisons across
all hypotheses using false discovery rates (FDR) (44). The FDR analyses included all 124
global comparisons: (8 SNPs * 2 ethnic groups * 3 baseline measures [PANSS total, positive
and negative]) + (2 haplotypes * 2 ethnic groups * 3 baseline measures) + (8 SNPs * 2 ethnic
groups * 4 treatment measures [PANSS total, positive and negative plus time to
discontinuation]). Predictably, none of the uncorrected significant differences described here
survived FDR correction for multiple comparisons.
Project Context
RGS4 was the third gene completed and analyzed in the CATIE sample, and all SNPs genotyped
are reported. Additional investigations are underway (see http://www.med.unc.edu/~pfsulliv/




The sample for this report is 678 CATIE subjects who provided DNA samples. Of the 678
participants, the inferred ancestries were: 198 “Africa only” (29%), 397 “Europe only” (59%)
and 83 “Other” (12%). Days to discontinuation of treatment during CATIE Phase 1 ranged
from 6 to 611 days (mean ± standard deviation [sd] = 287 ± 199 days). The sample scores for
the PANSS total ranged from 33 to 133 (mean ± sd = 73.5 ± 17.5) at baseline. The PANSS
total scores during Phase 1 antipsychotic treatment ranged from 30 to 131 (mean ± sd = 68.8
± 19.3). Table 1 provides additional detail about the sample population.
Regional Map
Figure 1a depicts the genomic region of RGS4 and the SNPs that were genotyped: rs951436,
rs951439, rs2661319, rs2842030, rs10759, rs2063142, rs2841959 and rs2841977. The RGS4
gene spans 7.2 kb of human chromosome 1q23.3.
Definition of Linkage Disequilibrium (LD) Blocks
The eight markers used to genotype the RGS4 gene define two linkage disequilibrium (LD)
blocks (Figure 1 b,c). The ~7-kb LD block 1 includes the putative promoter region, exon 1,
and part of the first intron. The ~34-kb LD block 2 includes the 3′ untranslated region and
downstream sequence. The LD block structure is similar in the African, European and Other
ancestry groups (Supplementary Table 1).
RGS4 SNP Data and Ethnic Stratification
Table 2 contains results for the SNPs genotyped along with reference data. Although no HWE
tests were less than a significance level corrected for multiple comparisons, the allele
frequencies for many of these SNPs were divergent in our sample as well as in reference data
from dbSNP and HapMap. Six of the eight SNPs had no serious issues in regard to deviation
from Hardy-Weinberg Equilibrium (HWE). There were no HWE problems with two SNPs
(rs951436 and rs951439) and no serious problems for two other SNPs (rs2661319 and
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rs2842030). Two SNPs had HWE deviations when all subjects were considered together but
had no meaningful departure when stratified by ancestry (rs2063142 and rs2841977); review
of the genotype frequencies suggest that these SNPs have different genotype frequencies by
ancestry so that HWE departures are expected if computed over all subjects.
Finally, rs10759 and rs2841959 showed HWE deviations in subjects with European ancestries.
We compared rs10759 to the HapMap CEU data and found that the minor allele frequencies
(MAFs) were similar (0.31 versus 0.28) as were the observed heterozygosities (0.36 versus
0.43) and that this SNP is in a highly conserved recombination hotspot. rs2841959 again has
similar MAF (0.49 versus 0.46) in comparison to HapMap CEU and is in a region with some
evidence of selection in Europeans. Overall, there are multiple reasons for HWE deviation,
including technical failures and population genetic phenomena (47), and these possibilities
should be kept in mind when interpreting the findings from these two SNP.
RGS4 genotype association with Baseline PANSS Scores
Analyses of baseline PANSS scores following ethnic stratification using sex and age as
covariates indicated association of rs2842030 specifically in patients of European ancestry
(P=0.021; Table 3). Similar baseline PANSS score trends across all ancestries prompted
exploratory analyses of the combined sample using ancestry, age and sex as co-variates. A
significant difference among genotypes was found at two consecutive LD block 1 markers,
rs2661319 (P=0.049) and rs2842030 (P=0.015; Table 3).
Haplotype association of baseline PANSS scores
Permutation-based analyses of haplotype-based baseline PANSS scores failed to show a global
significant difference in strata defined by African (P=0.091) and European (P=0.065) reported
ancestry. However, in an exploratory fashion, we noted that a LD block 1 haplotype – rs951436
allele A, rs951439 allele C, rs2661319 allele G and rs2842030 allele T (A-C-T-G) – showed
a statistically significant PANSS total score in subjects of both African (P=0.048) and European
ancestry (P=0.017) (Supplementary Table 2). None of the baseline associations survive FDR
correction for multiple comparisons of the 124 hypotheses tested concerning both baseline and
treatment response association.
Treatment Response—Using GEE models to include all available longitudinal data, SNP
by treatment analyses for PANSS total indicated a significant difference only among the group
of African ancestry and RGS4 marker rs951439 (P=0.024; Supplementary Table 3).
Exploratory analyses using PANSS positive and negative scores as the dependent variable
revealed that both PANSS positive (P=0.037) and negative (P=0.049) responses contributed
to the significant rs951439 PANSS total response difference (Supplementary Table 3). In
addition, the exploratory analyses of PANSS positive and negative response scores indicated
association of the the rs2842030 (P=0.023) and rs10759 (P=0.025) markers specifically in
PANSS positive response among patients of African ancestry (Supplementary Table 3). The
rs951439 and rs2842030 markers were sufficiently polymorphic in both the African and
European ancestry samples to result in sample cell numbers ranging from 5 to 54. Figures 2
and 3 summarize the RGS4 marker by treatment response data in the Africa only and Europe
only strata. Supplementary Table 4 presents additional RGS4 marker data that are based on
some sample cell numbers <5 but may represent important treatment response differences.
RGS4 genotype association with Phase 1 Time to Discontinuation of Treatment
When stratified by inferred ancestry, there was a significant rs951439 genotype by treatment
interaction in subjects of African ancestry (P=0.013) but not in subjects of European ancestry
only (P = 0.429). Patients of African ancestry with rs951439 genotype CC continued on
perphenazine (391 ± 63 days) significantly longer than ziprasidone (124 ± 46 days) (Figure
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2a). No other significant differences between perphenazine and the second-generation
antipsychotics were present after stratification by RGS4 genotype (Supplementary Table 4).
RGS4 genotype association with Phase 1 Drug Treatment: PANSS Total Scores
Patients of African ancestry and rs951439 genotype CC randomized to perphenazine treatment
demonstrated significantly greater improvement than patients treated with quetiapine or
risperidone. The average PANSS total score during perphenazine treatment (59.11 ± 3.45) was
29% better on average in comparison to ziprasidone treatment (76.48 ± 4.47; P=0.002) and
19% compared to quetiapine treatment (70.17 ± 2.41; P=0.010) (Figure 2c). Patients of African
ancestry and rs951439 genotype CT responded significantly worse to perphenazine (70.61 ±
2.42) than olanzapine treatment (63.51 ± 1.55; P=0.007). There were no significant differences
between perphenazine and second-generation antipsychotics among rs951439 genotypes in
patients of European ancestry (Supplementary Table 5). The associations with treatment
response do not survive FDR correction for multiple comparisons of the 124 hypotheses tested
here on baseline and treatment responses.
RGS4 genotype association with Phase 1 Drug Treatment: PANSS Positive and Negative
Scores
In a set of exploratory analyses, given the significant findings for PANSS total, we next
analyzed the PANSS positive and negative symptoms using the same analytical strategies.
Among patients of African ancestry and rs951439 CC genotype, the response to perphenazine
(13.74 ± 1.44) was significantly more positive than the response to ziprasidone (18.76 ± 1.21;
P=0.009) (Figure 2e; Supplementary Table 6). Among patients of African descent with the
rs2842030 TT genotype, response to perphenazine was indistinguishable from response to
olanzapine but significantly better than responses to quetiapine, risperidone and ziprasidone.
The average PANSS positive score was decreased by more than 30% during perphenazine
treatment (11.60 ± 1.64) and olanzapine treatment (11.60 ± 0.65) compared to treatments with
quetiapine (16.53 ± 0.98; P=0.011), risperidone (16.70 ± 0.78; P=0.006) and ziprasidone (18.57
± 0.52; P<0.001) (Figure 3e). Patients with rs2842030 genotype TT also appeared to respond
more positively to both perphenazine and olanzapine than those of rs2842030 genotype GG or
GT (Figure 3e; Supplementary Table 6). For PANSS negative scores, patients of African
ancestry and rs951439 genotype CC had significantly greater improvement during treatment
with perphenazine (17.27 ± 1.00) than quetiapine (20.39 ± 0.96; P=0.024) or ziprasidone (21.45
± 0.88; P=0.002). Patients of African ancestry and rs951439 genotype CT responded with
significantly higher PANSS negative scores during treatment with perphenazine (20.74 ± 0.76)
than olanzapine (18.33 ± 0.78; P=0.017) or quetiapine (17.75 ± 0.90; P=0.010) (Figure 2g;
Supplementary Table 7).
Discussion
The present study revealed an association of genetic variants in the RGS4 gene with alterations
in the baseline PANSS total score and with differential responsiveness to antipsychotic
treatment medications. The variants in the 5′ region of RGS4 have not been analyzed yet for
regulatory functions, and additional experiments will be required to identify the functional
variants marked by association of the genotyped SNPs. However, the difference in baseline
PANSS total score among RGS4 markers in the 5′ region of the gene may be consistent with
the hypothesis that differential regulation of RGS4 contributes to the severity of schizophrenia
symptoms (30). The different treatment responses among RGS4 genotypes, based on changes
in PANSS scores and time to discontinuation of treatment, is consistent with our working
hypothesis that (a) the pharmacologic actions of antipsychotic treatments could be influenced
by RGS4 expression levels; and (b) certain RGS4 genotypes may be useful for predicting the
efficacy of a particular treatment regimen in specific, ethnically defined patient populations.
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We caution that these are exploratory analyses and all results require confirmation.
Nonetheless, the present findings, in combination with other data, provide additional evidence
that RGS4 variants correlate with certain phenotypic characteristics of individuals with
schizophrenia. For example, reduction in the volume of the dorsolateral prefrontal cortex
(DLPFC, a brain region implicated in schizophrenia) has been shown in first episode patients.
Recently, Prasad et al (48) reported that this reduction correlates with RGS4 SNP18 genotype
GG. RGS4 SNP18 is the reverse complement of rs2661319, for which we describe an
association of the TT genotype (equivalent to the SNP18 GG genotype) with higher baseline
PANSS Total scores. Taken together, Prasad et al (48) and the present study suggest that
individuals with the rs2661319 TT genotype have quantifiably more severe disease symptoms,
characterized by both PANSS total score and a neuroanatomical deficit in DLPFC.
There is a distinct ancestral difference in the correlations between RGS4 genotype and
treatment responses. In the sample of African ancestry patients, the rs951439 CC genotype
correlated with: (a) longer time to discontinuation for those individuals in the perphenazine
group compared to the quetiapine or ziprasidone groups; (b) decreased PANSS total and
PANSS negative symptoms scores for individuals in the perphenazine treatment group
compared to the quetiapine or ziprasidone treatment groups; and (c) decreased PANSS positive
symptoms score for the individuals in the perphenazine treatment group compared to those
patients in the ziprasidone treatment group (Figure 2). Nearly identical results were observed
for individuals of African descent and rs2842030 genotype TT (Figure 3). In contrast, patients
of European descent and in the risperidone group differed by RGS4 genotype. Among European
ancestry patients, rs951439 genotype CC or rs2842030 genotype TT correlated with: (a)
decreased time to discontinuation of treatment compared to the opposite homozygous
genotype; (b) a trend toward increased PANSS total scores; and (c) increased PANSS positive
scores compared to same-genotype individuals treated with perphenazine (Figures 2 and 3).
Particularly striking are the apparent differential responses to ziprasidone. Individuals of
African ancestry and rs951439 CC genotype appeared to be poorer responders to ziprasidone
compared to other rs951439 genotypes, as evidenced by decreased time to discontinuation and
higher PANSS scores during treatment (Figure 2). In contrast, these features that characterize
the group of patients on ziprasidone were indistinguishable among rs951439 genotypes in the
European ancestry strata (Figure 3). A summary of the characteristics used to infer treatment
responses stratified by ethnic descent and RGS4 genotype is provided in Table 4. Perphenazine
and olanzapine appeared to be particularly effective in individuals of African ancestry and
either rs951439 CC genotype or rs2842030 TT genotype. Among patients of European
ancestry, risperidone was effective in those with rs951439 genotype TT or rs2842030 genotype
GG but less effective in individuals of rs951439 genotype CC or rs2842030 genotype TT (Table
4).
Antipsychotic medications act to modulate G-protein coupled receptors (GPCRs) stimulated
by dopamine, acetylcholine and serotonin. RGS4 shortens the duration of signaling via GPCRs
by acting as a GTPase activating protein (GAP), thereby accelerating the deactivation of the
heterotrimeric G protein following receptor activation. Therefore, alterations in RGS4
availability or function could alter the effectiveness of antipsychotic medications. The
association data presented here suggest that RGS4 plays an important and differential role in
modulating the transduction of signals from GPCRs targeted by antipsychotic medications.
These results also emphasize the importance of including multiple ethnic groups in a study
design and the importance of collecting substantially larger samples of under-represented
ethnic groups than typically done in such studies. The present study of 678 individuals
including 198 patients of African descent provides initial evidence that there may be more than
one functional variant in RGS4 that contributes to schizophrenia disease etiology and to
characteristic phenotypes that may reflect in part antipsychotic treatment response. The data,
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while recognizing that these were obtained from a relatively small sample size, suggests further
exploration to determine whether the variants derive from different ancestries. As with all
association studies, replication of the findings in this first report is essential (49). However,
together with numerous association analyses, these results provide additional support for the
hypothesis that RGS4 is part of a complex biological mechanism that underlies schizophrenia
pathophysiology and continues to influence treatment outcomes throughout life by affecting
antipsychotic treatments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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RGS4 genomic region, markers genotyped and linkage disequilibrium (LD) block structure.
(a) RGS4 genomic structure. At the top are general genomic data along with an ideogram
depicting chromosomal position. The topmost track shows RGS4 with the direction of
transcription indicated by > (5′ → 3′), exons by vertical bars, and “U” indicates the presence
of an untranslated region. The next track shows SNPs genotyped in the present study. (b)
RGS4 LD block structure in the entire 678-individual sample. The genotyped SNPs define two
LD blocks in the RGS4 gene: a 7-kb block including the promoter region and exon 1, and a
34-kb 3′ block. Pairwise D′ values (X 100) are indicated. (c) RGS4 LD block structure depicted
with pairwise r2 values.
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Association of RGS4 marker rs951439 genotype with antipsychotic treatment response.
Among the 198 patients of African ancestry, rs951439 genotype CC continue on perphenazine
treatment significantly longer than ziprasidone treatment (a) and have significantly lower
PANSS scores (c, e, g) during treatment with perphenazine compared to ziprasidone. Patients
of rs951439 CC genotype and African ancestry in the perphenazine group exhibits differences
compared to patients in the quetiapine group when the PANSS total and PANSS negative scores
are used as dependent variables (c, g). Among the 397 patients of European ancestry, no
significant global differences between perphenazine and second-generation antipsychotics
were observed (b, d, f, h). However, patients with rs951439 TT genotype in the risperidone
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group appeared to remain on risperidone longer (b) and exhibited less severe positive symptoms
during risperidone treatment (f) than genotype CC. Each bar represents response data from 5–
48 patients. Detailed analyses are presented in Supplementary Tables 3–7. * indicates
significant difference (P<0.05) for both global and pairwise comparisons with perphenazine
by multiple linear regression with GEE.
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Association of RGS4 marker rs2842030 genotype with apparent antipsychotic treatment
response. Among the 198 individuals of African ancestry, the rs2842030 genotype was
significantly correlated with PANSS positive scores: genotype TT in the perphenazine group
had better scores compared to quetiapine, risperidone and ziprasidone groups; there was no
difference with between perphenazine and olanzapine (e). Trends similar to those observed for
rs951439 (Figure 2) are evident in the African ancestry response associations for rs2842030
(a, c, g); however, only the associations using PANSS positive scores reached global
significance. Among the 397 patients of European ancestry, no significant global differences
between perphenazine and second-generation antipsychotics were observed (b, d, f, h).
However, the group of individuals with the rs2842030 GG genotype on risperidone remained
on treatment longer (b) and exhibit less severe positive symptoms during risperidone treatment
(f) than genotype TT. Each bar represents response data from 5–54 patients. Detailed analyses
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are presented in Supplementary Tables 3–7. * indicates significant difference (P<0.05) for both
global and pairwise comparisons with perphenazine by multiple linear regression with GEE.
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Table 4
Summary of ethnic stratification of RGS4-genotype dependent antipsychotic treatment effectiveness, defined by
PANSS scores and time remaining on a specific drug treatment.
Africa only Europe only
rs951439 CC TT CC TT
Perphenazine + 0 0 0
Olanzapine + 0 0 0
Quetiapine − + 0 0
Risperidone + 0 − +
Ziprasidone − + 0 0
rs2842030 TT GG TT GG
Perphenazine + 0 0 0
Olanzapine + 0 0 0
Quetiapine − 0 0 0
Risperidone − 0 − +
Ziprasidone − + 0 0
Among patients of African ancestry, perphenazine and olanzapine were superior to the other antipsychotic treatments in individuals homozygous for the
rs951439 CC or rs2842030 TT genotype; there was no apparent difference among treatments for the rs951439 TT or rs2842030 GG genotype. Among
those of European ancestry, the only differences were in the response to risperidone. “+” indicates improved schizophrenia symptoms for genotype-drug
combination; “−” indicates worsened schizophrenia symptoms; “0” indicates no apparent differential effect of antipsychotic treatment. Criteria: >25%
difference in time to discontinuation of treatment compared to opposite homozygous genotype under same drug treatment or significantly altered same-
genotype PANSS total, positive or negative score.
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